Rasna Therapeutics Inc. Overview
Industry: Biotechnology
Sector: Healthcare
Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. The company is developing RASP-201, a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase, a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301, an NCE for NPM1, currently at the pre-clinical stage to treat refractory AML with reduced toxicity. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York.
Rasna Therapeutics Inc. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Rasna Therapeutics Inc. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Rasna Therapeutics Inc. Competitors
Rasna Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans